Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Effect in Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* disease duration less than 3 years from the time of diagnosis, age more than 18 years, a diagnosis of RA according to the 2010 ACR/ EULAR Classification criteria for RA diagnosis , active disease according to DAS-28, for those receiving nonsteroidal anti-inflammatory drugs and corticosteroids, the dosage had to be stable for at least 2 weeks before screening.~Exclusion Criteria:~* Patients with allergic, and infectious diseases, patients receiving steroids for the first time within 2 weeks before the study, patients with hypercalcemia, hypercalciuria, nephrolithiasis, or neoplastic diseases were excluded from the study. We also excluded patients on any biologic therapy and patients with prior use of leflunomide, hydroxychloroquine, or sulphasalazine for more than 2 months.

- Gender: ALL
- Minimum Age: 33 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- group II (Type: OTHER): 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) weekly for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).